IFX 1

Drug Profile

IFX 1

Alternative Names: CaCP 29; IFX-1

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Beijing Mabworks Biotech; InflaRx
  • Developer InflaRx
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5a inhibitors; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa; Sepsis; Systemic inflammatory response syndrome
  • Phase I Inflammation

Most Recent Events

  • 04 Nov 2016 Phase-II clinical trials in Hidradenitis suppurativa in Greece (IV) (EudraCT2016-002988-33)
  • 03 Mar 2016 Phase-I clinical trials in Inflammation in Germany (IV) before March 2016
  • 03 Mar 2016 Phase-II clinical trials in Systemic inflammatory response syndrome in Germany (IV) (InflaRx pipeline, March 2016; NCT02866825)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top